Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease

Therapeutics and Clinical Risk Management

Volumn 2, Issue 3, 2006, Pages 297-301

  Cheng, Steven ^a   Coyne, Daniel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; BONE MORPHOGENETIC PROTEIN; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMIN D RECEPTOR;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FIBROSIS; LONG TERM CARE; MORTALITY; NAUSEA; NODULAR HYPERPLASIA; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VOMITING;

EID: 33748441159     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.3.297     Document Type: Review

References (42)

1. Agarwal R, Acharya M, Tian J, et al. 2005. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int, 68:2823-8.
2. Baker LR, Abrams L, Roe CJ, et al. 1989. 1,25(OH)2D3 administration in moderate renal failure: A prospective double blind trial. Kidney Int, 35:661-9.
3. Barrat F, Cua D, Boonstra A, et al. 2002. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type (Th1) and Th2 inducing cytokines. J Exp Med, 195:603-16.
4. Bellows C, Reimers S, Heersche J. 1999. Expression of mRNAs for type 1 collages, bone sialoprotein, osteocalcin and osteopontin at different stages of osteoblastic differentiation and their regulatikons by 1,25-dihydroxyvitamin D. Cell Tissue Res, 297:249-59.
5. Boonstra A, Barrat FJ, Crain C, et al. 2001. 1-alpha-25-dibydroxyvitamin D3 has direct effect on naïve CD4+ T cells to enhance the development of Th2 cells. J Immunol, 167:4974-80.
6. Brandi L, Egfjord M, Olgaard K. 2002. Pharmacokinetics of 1,25 (OH)2D3 and 1(OH)D3 in normal and uraemic men. Nephrol Dial Transplant, 17:829-42.
7. Brown AJ, Finch J, Slatopolsky E. 2002. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphorus transport. J Lab Clin Med, 139:279-84.
8. Cato A 3rd, Cady WW, Soltanek C, et al. 1998. Effect of hemodialysis on the pharmacokinetics. of 19-nor-1 alpha,25-dihydroxyvitamin D2. Am J Kidney Dis, 32:S55-60.
9. Coburn J, Maung H, Elangovan L, et al. 2004. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis, 43:877-90.
10. Coyne, D, Charya M, Qiu P, et al. 2006. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis, 47:263-76.
11. Coyne DW, Grieff M, Ahya SN, et al. 2002. Differential effects of acute administration of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis, 40:1283-8.
12. Dobrez D, Mathes A, Amdahl M, et al. 2004. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant, 19:1174-81.
13. Drissi H, Pouliot A, Koolloos C, et al. 2002. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa2 gene promoter. Exp Cell Res, 274:323-33.
14. Dusso AS, Brown AJ. 1998. Mechanisms of vitamin D action and its regulation. Am J Kidney Dis, 32(Suppl):13-24.
15. Goodman WG, Goldin J, Kuizon BD, et al. 2003. Coronary-artery calcifications in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 342:1478-83.
16. Goldsmith D, Ritz E, Covic A. 2004. Vascular calcification: a stiff challenge for the nephrologist; Does preventing bone disease cause arterial disease? Kidney Int, 66:1315-33.
17. Hamdy N, Kanis J, Beneton M, et al. 1995. Effect of alfacalcidol on natural course of renal bone disease in mild and moderate renal failure. BAV, 310:358-63.
18. Kramer H, Toto R, Peshock R, et al. 2005. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol, 16:507-13.
19. Levin A, Li Y. 2005. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int, 68:1973-81.
20. Li Y, Spataro B, Yang J, et al. 2005. 1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int, 68:1500-10.
21. Llach F, Yudd M. 2001. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathydoisim. Am J Kidney Dis, 38(Suppl):S45-50.
22. Martin KJ. 2001. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double blind, multicenter, randomized study. Am J Kidney Dis, 38(Suppl):S57-63.
23. Martin KJ, Gonzalez EA, Gellens M, et al. 1998a. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol, 9:1427-32.
24. Martin KJ, Gonzalez EA, Gellens ME, et al. 1998b. Therapy of secondary hyperparathyroidism with 19-nor-1alpha, 25-dihydroxyvitamin D2. Am J Kidney Dis, 32(2 Suppl 2):S61-6.
25. McCarron DA, Muthers RS, Lenfesty B, et al. 1982. Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int, 22:662-70.
26. Mee A, Davenport L, Hoyland J, et al. 1996. Novel and sensitive detection systems for the vitamin D receptor - in situ reverse transcriptase-polymerase chain reaction and immunogold cytochemistry. J Mol Endocrinol, 16:183-96.
27. Nordal KP, Dahl E. 1988. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab, 67:929-36.
28. Pitts TO, Piraino BH, Mitro R, et al. 1988. Hyperparathyroidism and 1, 25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab, 67:876-81.
29. Qunibi WY, Nolan CA, Ayus JC. 2002. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Supplemental, 82:73-80.
30. Reichel H, Deibert B, Schmidt-Gayk H, et al. 1991. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant, 6:162-9.
31. Russell J, Lettieri D, Sherwood LM. 1986. Suppression by 1, 25 (OH) D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology, 119:2864-6.
32. Sigris M, Bungay P, Taal M, et al. 2006. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant, 21:707-14.
33. Silver J, Naveh-Many T, Mayer H, et al. 1986. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest, 78:1296-301.
34. Slatopolsky E, Weerts C, Thielan J, et al. 1984. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest, 74:2136-43.
35. Sprague SM. 2001. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis, 38(Suppl):S51-6.
36. Staniforth M, Cheng S, Coyne D. 2005. Once weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol, 63:454-60.
37. Staeva-Vieira T, Freedman L. 2002. 1,25-dihydroxyvitamin D inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol, 168:1181-9.
38. Tan X, Liu Y. 2005. Paricalcitol attenuates renal interstitial fibrosis in mouse models of obstructive nephropathy [poster]. The Annual Meeting of the American Society of Nephrology, 11-14 November, Philadelphia, PA, USA. FPO422
39. Teng M, Wolf M, Lowrie E, et al. 2003. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Engl J Med, 349:446-56.
40. Teng M, Wolf M, Ofsthun M, et al. 2005. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol, 16:1115-25.
41. Virdi AS, Cook LJ, Oreffo RO, et al. 1998. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mo Biol, 44:1237-46.
42. Yang J, Liu Y. 2002. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol, 13:96-107.